Home Category Region Publishers About Us Contact Us
Japanese Korean Chinese
Home > Market Research Report > Pharmaceutical > Pharmaceutical Companies > Pharma-Biotech Alliance Management--Critical Success Factors
Category
Pharmaceutical (4988)
Bone Disease Treatment (46)
Cancer (883)
Diabetes (159)
Drug Delivery System (184)
Drug Discovery (1403)
Generic Drugs (128)
Infectious Disease (406)
Mental Disease (98)
Neurodegenerative Disease (180)
Obesity Treatment (49)
OTC Drug (149)
Pharmaceutical Companies (561)
Prescription Drugs (120)
Regulation (122)
Vaccines (178)
Veterinary Medicine (28)
Market Research Report

Pharma-Biotech Alliance Management--Critical Success Factors

Published by Frost & Sullivan
Published May, 2006 Product code 45014
Content info  
Price
US $ 6500 Web Access (Regional License)
US $ 7000 Hard Copy & Web Access (Regional License)


Pharma-Biotech Alliance Management--Critical Success Factors published by Frost & Sullivan in May, 2006. This report price starts from US $ 6500.

Introduction

Abstract

This Frost & Sullivan research service entitled Pharma-Biotech Alliance Management - Critical Success Factors provides examples of key pharma-biotech and biotech-biotech alliances in the industry, looking at key trends, drivers and challenges in the industry and critical success factors that are required in managing an alliance effectively. In this research, Frost & Sullivan's expert analysts thoroughly examine the pharma and biotech industry in relation to alliance management.

This analysis is available through our Pharmaceutical & Biotechnology Growth Partnership Services program. With this program, clients receive industry-leading market research such as this, along with technical and econometric data and many interactive features including Analyst Inquiry Time and Client Councils.

Table of Contents

1. Executive Summary

  • 1. Overview
    • 1. Summary of Pharma-Biotech Alliance Management - Critical Success Factors

2. Exchange Rates

  • 1. Exchange Rates
    • 1. Currency Exchange Rates

3. Research Scope and Methodology

  • 1. Scope and Methodology
    • 1. Research Methodology

4. Introduction and Segmentation

  • 1. Introduction
    • 1. Background
    • 2. Segmentation

5. Pharmaceutical Industry Overview

  • 1. Overview
    • 1. Overview of the Pharmaceutical Industry
    • 2. Identification of the Challenges Facing Pharmaceutical Companies

6. Biotechnology Industry Overview

  • 1. Overview
    • 1. Overview of the Biotechnology Industry
    • 2. Identification of the Challenges Facing Biotechnology Companies

7. Key Challenges in Alliance Management

  • 1. Challenges
    • 1. Challenges

8. Key Drivers in Alliance Management

  • 1. Drivers
    • 1. Drivers

9. Pharma - Biotech Alliances

  • 1. Alliances
    • 1. Introduction
    • 2. Overview and Key Trends
    • 3. Key Pharma-Biotech Alliances
    • 4. Case Study - Novartis

10. Biotech - Biotech Alliances

  • 1. Alliances
    • 1. Introduction
    • 2. Overview and Key Trends
    • 3. Key Biotech-Biotech Alliances
    • 4. Case Study - Serono

11. Critical Success Factors

  • 1. Success Factors
    • 1. Success Factors

12. Strategic Recommendations for Alliance Management

  • 1. Recommendations
    • 1. Recommendations
    • 3. Emerging / Small Biotech Companies
    • 4. Larger Biotech / Biopharmaceutical Companies
    • 5. Large Pharma Companies
    • 6. Summary

13. Frost & Sullivan Awards

  • 1. Frost & Sullivan Awards for the European Pharma and Biotech Industry
    • 1. 2006 Frost & Sullivan Awards
    • 2. Entrepreneurial Company Award
    • 3. Technology Innovation Award
    • 4. Competitive Strategy Leadership Award

14. Key Industry Participants

  • 1. Industry Participants
    • 1. Major Participants

15. Decision Support Databases

  • 1. Biotech
    • 1. Number of Biotech Companies
    • 2. Number of Employees in Biotech Companies
    • 3. EPO Biotech Patent
    • 4. Government R&D Investment in Biotechnology
    • 5. Percent Government Biotech R & D Investment
    • 6. Private Investment in Biotechnology
    • 7. Per cent Private Investment in Biotechnology
  • 2. Pharmaceutical R&D
    • 1. Pharmaceutical R&D Expenditure
    • 2. Percent Pharmaceutical R&D Expenditure
Back to Top